Based in Gyeonggi-Do, South-Korea, PIKE specializes in identifying and developing biomaterials and technologies important for use in connection with drug delivery systems (DDS) and drug formulation. PIKE’s capabilities create opportunities for pharmaceutical companies to extend the life-cycle of their products or accelerate drug candidates toward successful markets. PIKE’s three main technology platforms are: (i) SDNP for water-insoluble or poorly soluble drugs; (ii) BioGel for protein and peptide drugs (Controlled-Release DDS); and (iii) PPA for cytotoxic drugs (Site-Specific DDS). Company website does not exist.